211 related articles for article (PubMed ID: 23326931)
1. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
Agbalaka A; Schwenke K; Litzenburger B
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
[TBL] [Abstract][Full Text] [Related]
2. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
[TBL] [Abstract][Full Text] [Related]
3. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
4. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.
Strick V
Curr Med Res Opin; 2014 Oct; 30(10):2085-92. PubMed ID: 24983745
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
J Pain Palliat Care Pharmacother; 2013 Aug; 27(3):225-34. PubMed ID: 23957433
[TBL] [Abstract][Full Text] [Related]
6. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
Lange T; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114
[TBL] [Abstract][Full Text] [Related]
7. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
Richter U; Waldmann-Rex S; Lehmann U
Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
Schwittay A; Sohns M; Heckes B; Elling C
Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
11. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
12. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
13. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
[TBL] [Abstract][Full Text] [Related]
14. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
[TBL] [Abstract][Full Text] [Related]
15. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
[TBL] [Abstract][Full Text] [Related]
16. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A
MMW Fortschr Med; 2013 Jan; 155(1):64. PubMed ID: 23573727
[No Abstract] [Full Text] [Related]
17. Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients.
Schikowski A; Krings D; Schwenke K
J Pain Res; 2015; 8():1-8. PubMed ID: 25565884
[TBL] [Abstract][Full Text] [Related]
18. Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes.
Tedeschi A; De Bellis A; Francia P; Bernini A; Perini M; Salutini E; Anichini R
J Diabetes Res; 2018; 2018():1081792. PubMed ID: 29675431
[TBL] [Abstract][Full Text] [Related]
19. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
